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INTRODUCTION
Changes in resting energy expenditure (REE) in cancer patients have been a controversial topic in literature. Substantial evidence supports elevations in REE during the tumour-bearing state. Elevated REE can potentially promote weight loss which can produce suboptimal clinical outcomes and increase morbidity and mortality risk [1] . Furthermore, elevated REE in conjunction with poor oral intake typically seen in cancer patients serve a significant role in accelerating weight loss and progressing to the development of malnutrition and cancer cachexia [2] . Current published findings depict inconsistencies in metabolic changes. Various authors propose that different cancers cause varying degrees of metabolic derangements. Fredrix et al [3] observed greater elevation of REE in lung cancer patients than gastric-colorectal cancer patients. Cao et al [4] found elevated REE in patients with oesophageal, gastric, pancreatic and lung cancers when compared to a healthy control group, whereas colorectal cancer patients showed no elevation in REE. Merli et al [5] and Xu et al [6] saw increased REE in patients with hepatocellular carcinoma and urologic cancer, respectively. However, authors for example Fearon et al [7] observed no significant differences in REE in colon and lung cancer patients and Trutschnigg et al [8] reported insignificant differences in advanced cancer patients.
Energy expenditure is the result of metabolic activities from various body tissues and organs. Major organs, such as the lungs and liver, are metabolically demanding and contribute to REE due to its continuous functioning and higher energy demands to perform metabolic processes irrespective of the body's physical state and resting conditions. Fat free mass (FFM) is considered to be the largest contributor to REE suggested to provide 53-88% of REE variation [9, 10] . It would be valid to conclude that REE is decreased if loss of FFM becomes apparent under any circumstances, including cancer. This has not been the case as weight loss is frequently reported and observed in cancer patients. Weight loss associated with cancer is considered undesirable due to losses from either fat mass, FFM or both which serve important sources of energy during periods of acute hypermetabolism [1] . It has also been hypothesised that muscular atrophy typically observed in clinical settings is associated with poor tolerance of cancer treatment procedures and, hence, poor clinical outcomes [2] .
Tumour-bearing is proposed to elevate energy expenditure. However, there is uncertainty surrounding this. It has been suggested [2] that the tumour itself is unlikely to be the direct cause of elevated energy expenditure as tumours rarely contribute more than 5% of body weight. A plausible explanation may be that presence of tumours can exert an indirect effect on energy expenditure. The production of biochemical mediators stimulated by tumour growth may alter metabolism [2] and promote the inflammatory response which could contribute to hypermetabolism [11] .
Although nutritional adequacy may be achieved to limit weight loss from FFM, the uncertainty of the metabolic environment may impede the maintenance or restoration of FFM [2, 12] . Identifying the extent to which REE is altered and understanding the cancer subtypes which cause the greatest increases in REE is important from a clinical perspective to limit anticipated weight loss as FFM and optimise clinical outcomes. The primary aim of this study was to establish the difference in REE between cancer patients and healthy controls. The secondary aim was to distinguish the differences in REE between cancer subgroups. As FFM is considered to be a large contributor to REE [9] , it is appropriate to use measured REE per kg FFM. The use of healthy control groups was deemed appropriate to use as the standard for comparison to determine metabolic changes in cancer patients.
METHODS

Literature search
Literature searches were conducted by VN using the databases PubMed, Cochrane Library, Medline, Science Direct, Scopus, Web of Science, Wiley Online Library, and ProQuest Central from the earliest record to March 2014 to obtain as many potentially relevant studies as possible. The following search terms, 'resting energy expenditure', 'resting metabolic rate', 'basal metabolic rate', 'cancer', and 'neoplasm' were used. Reference lists from included studies were reviewed to obtain additional relevant articles. The journals, Nutrition and Cancer, and Cancer and Metabolism were also searched using the above search terms.
Study selection
Studies in which the title included one or more of the search terms were obtained from the literature search. The abstracts of the studies were reviewed by VN and MB for relevance. Studies were included if REE was expressed as kilojoules (kJ) or kilocalories (kcal) per kilogram FFM (REE/FFM), body composition was measured, participants were adult humans with cancer, healthy control groups were defined and used, statistical values presented as mean ± standard deviation (mean±SD) or mean ± standard error of the mean (mean±SEM), and studies were published in English. Studies that measured REE, as REE/FFM, in cancer patients but did not include control groups were also included. Baseline REE measurements from intervention (pre-test/post-test) studies were included in the data set.
Data extraction
Study characteristics including the authors, source, publication year, cancer type, and the use of control subjects were tabulated. Baseline REE, presented as kJ or kcal per kg FFM, the number and type of subjects were collated into a Microsoft Office Excel spreadsheet. The method used to assess REE and the method used to assess body composition were also recorded, these were divided into more accurate and reliable methods (Dual energy x-ray absorptiometry DEXA, total body water, or total body potassium) and field methods (bioelectrical impedance assessment or skinfold anthropometry) to assess study quality. The baseline REE was the measurement prior to the cancer patients' undergoing various treatments.
Statistical analysis
The baseline REE values and the number of participants (cancer patients and healthy controls) were used to complete the meta-analysis conducted by MB. The meta-analysis was conducted using STATA/IC V14 ( StataCorp LP, College Station, Tx) using the metan command [13] . All meta-analyses were conducted using random effects as heterogeneity was anticipated. Differences in REE amongst cancer types were also determined through a subgroup analysis. In order to account for the use of the same control subjects for some studies the sample sizes were divided by the number of times the control group was used [14] . Additionally independent subgroups within a study were considered separately in the primary analysis [15] . In order to investigate potential confounding variables secondary analyses were also conducted to investigate the effect of healthy versus hospitalised/disease controls, weight losing versus weight stable cancer patients and controls, gender, and year of publication (pre or after 2000). Results are presented as weighted mean differences (WMD) between groups with 95% confidence intervals (95%CI). Statistical significance of the differences between the groups is calculated using metaregression (metareg in STATA V14.0). Study quality comparing those studies using a more accurate and reliable measure of body composition assessment compared with a field measure was also assessed using metagression. Figure 1 shows a flowchart of the extraction process. A total of 205 abstracts were obtained from the initial literature search, 178 abstracts were excluded on the following basis: 85 studies expressed REE as kJ or kcal per day body weight or body cell mass, did not measure REE or body composition, or did not present data as mean±SD or mean±SEM; 56 were either review articles, educational papers, poster presentations, case reports, editorials or supplementary material; 12 studies were published in a language other than English; 11 studies were not on the subject of cancer; 7 studies were on animals; and 7 studies involved children. Twenty-seven studies were considered relevant for inclusion in this review [3-8, 11, 16-35] (Table  1) . Of these 27 studies, 14 studies included a healthy control group and the data from these studies were used to generate the meta-analysis ( Figure 2 ). Two studies used the cancer patients as their own control.
RESULTS
Search results
INSERT FIGURE 1
INSERT TABLE 1   INSERT FIGURE 2 The forest plot shown in Figure 2 represents data obtained from 1453 cancer patients and 1145 control participants. The mean difference in REE/FFM between cancer patients and healthy controls is 9.66kJ/kgFFM/day (95% CI 3.34,15.98) which suggests an overall increase in REE in cancer patients. The test for heterogeneity (Chi 2 =474.01 p < 0.001) suggested significant variation in REE/FFM among cancer types, the funnel plot presented in Figure 3 shows no evidence of publication bias but clearly emphasises the outlying value of the Wu et al study [35] .
INSERT FIGURE 3
The subgroup analysis ( Figure 4 ) represents data from 12 of the 14 studies included in the meta-analysis. Two studies were not included in the analysis as they did not distinguish between cancer subtypes. The subgroup analysis derived mean differences in REE for 6 cancer types. Lung, head and neck/oesophageal, pancreatic and urological cancers had elevations of 6.52kJ/kg FFM/day, 21.06kJ/kg FFM/day, 9.51kJ/kg FFM/day and 3.86kJ/kg FFM/day, respectively. Liver cancer illustrated the greatest elevation of 22.68kJ/kg FFM/day. All groups were significantly elevated with the exception of the gastric/colon cancer subgroup which showed an increase of 1.99kJ/kg/day FFM (95% CI -0.58,4.53). The head, neck and oesophageal group elevation while high was not significant when the Wu study was included however the funnel plot demonstrates that this study is a clear outlier (consistent with the funnel plot in Figure 5 ), reanalysis without this study showed an elevation in the head, neck and oesophageal group of 6.04 kJ/kg/day FFM (95%CI 2.27, 9.81) indicating that REE is increased in this group. There was no evidence of publication bias (asymmetry) in the subgroup analysis ( Figure 5 ).
INSERT FIGURE 4 INSERT FIGURE 5
When controls were divided into healthy (WMD 14.74 95%CI 1.99,27.50 kJ/kgFFM/day) or hospitalised/diseased (WMD 4.51 95%CI 1.00,8.01) elevation in REE in cancer patients were still significantly elevated in both groups and there was no difference between groups P=0.264. While there was no statistically significant difference between those identifying weight stable cancer patients and controls (WMD 6.55 95%CI 4.21, 8.90 kJ/kg FFM/day) and those identifying weight losing cancer patients and controls (WMD 4.49 95%CI -0.61,9.58 kJ/kg FFM/day) P=0.628, the elevation in the weight losing group only approached significance P=0.084. There was no effect of year of publication when a subgroup analysis was conducted dividing the dataset into publication year prior to (WMD 5.45 95%CI 1.54, 9.35 kJ/kg FFM/day) or after 2000 (WMD 23.51 95%CI 7.70, 39.32 kJ/kg FFM/day) P=0.092, the wide CI for the post 2000 publications was influenced by the Wu et al paper (without this paper the WMD for the post 2000 papers was 4.60 95%CI 3.21, 5.98 kJ/kg FFM day). Only 2 studies reported values by gender [29, 32] , there was no significant effect using meta regression (males WMD -3.33 95%CI -10.14, 3.47 kJ/kg FFM/day and females WMD 3.75 95% CI -2.79, 10.29 kJ/kg FFM/day) P=0.179. All studies assessed resting energy expenditure using indirect calorimetry. The study quality assessment also showed no significant effect of body composition method more accurate and reliable method (WMD 4.02 95%CI 0.76, 7.28 kJ/kg FFM/day) compared with field method (WMD 12.14 95%CI 3.16, 21.11 kJ/kg FFM/day) P=0.494.
DISCUSSION
This study sought to determine the difference in REE between cancer patients and control subjects through summarizing data available from case-control and pretest/post-test studies. The meta-analysis derived from 16 studies suggested an 8-9% increase in REE in cancer patients when compared to healthy control groups.
Cancer subtypes were shown in this analysis to generate different degrees of change in REE which is consistent with the previous notion of cancer type and tumour site affecting energy expenditure differently. While all subgroups showed an overall increase the difference was not significant for gastric and colon cancers and varied from 3.86 (95% CI 1.64, 6.08) kJ/kg FFM/day for Urologic cancers to 22.68(95% CI 10.80, 34.56) kJ/kg FFM/day for the single study in liver cancer. Generally the FFM and to a lesser extent the fat mass (FM) are considered the major contributors to the REE. The metabolic activity of the organs however cannot be overlooked for their role in explaining variation in REE particularly if their function is altered by malignancy. Metabolic activity can be defined as the respective processes which occur at a cellular level to enable proper function of an organ. While a high metabolic rate in an organ does not necessarily mean a higher metabolic rate is generated from cancer in that tissue, in some cases metabolic activity has been shown to be elevated in the diseased state with some major organs reportedly being more metabolically demanding than others. The lungs are considered as highly metabolically active organs and can utilise various substrates for normal function [36] which may somewhat explain for the elevations. According to the subgroup analysis ( Figure 4 ) pancreatic cancer was also observed to generate an increase in REE. As the pancreas possesses both endocrine and exocrine functions, it has the potential to influence metabolism through inflammatory processes or the altered use of substrates. It has been suggested the flux of glucose in cancer patients may be elevated suggesting increased glucose demand [37] . Given that incomplete oxidation of glucose is to be replaced by fat oxidation [4] this could result in an increase in energy expenditure of 1050-1260kJ/day[37] which would correspond to approximately 0.9kg fat loss/month. This could be a possible explanation for the progressive weight loss often observed in cancer patients. According to the subgroup analysis ( Figure 4 ), REE was also significantly altered in patients with head and neck and oesophageal cancer. Of the 3 studies reviewed, only 1 study was included in the analyses. Langius et al [27] reported no significant differences between cancer patients and control participants. Four studies investigating REE in oesophageal cancer patients were included in this review and analyses. Thomson [8, 11, 31 ]studying other cancer types have associated elevated REE with inflammatory cytokines, such as Creactive protein (CRP), interleukins 1 and 6 (IL-1; IL-6) and tumour necrosis factor (TNF). It has been suggested the contribution of humoral factors to hypermetabolism and cancer cachexia may be mediated by these cytokines and promote increased proteolysis, lipolysis and various glucose-synthesising pathways [38, 39] . This theory could be valid and applicable with this clinical population as weight loss in healthy individuals generally does not involve inflammatory processes. Although the subgroup analysis concluded patients with head and neck and oesophageal cancers experience metabolic derangements, it is important to consider the inconsistencies of the studies used in this subgroup. Given that more studies concerning oesophageal cancer were used in the subgroup analysis, this may bias the overall REE for this subgroup and may not accurately reflect metabolic alterations in patients with head and neck cancer.
Only one study included in the analyses looked at REE in cirrhotic patients with hepatocellular carcinoma (HCC) and documented increased REE. Merli et al [5] reported an average increase of 22.68kJ/kg/day FFM with weight-losing patients having higher REE than weight-stable patients. Tumour stage was not considered a major determinant of REE in cirrhotic patients with HCC as elevations in REE was consistently observed amongst patients, and nil correlations between tumour size and REE were made. Similar conclusions have been made in regard to other cancer types studied by other authors [5, 21, 32, 33] . However, these conclusions are opposed to findings from Jebb et al [26] who reported a reduction in REE in lung cancer patients when tumour size was reduced, this study used cirrhotic controls which may explain the differences in results. There was only one study included in the meta-analysis ( Figure 4 ) which studied REE in urologic cancer patients. Xu et al [6] observed a significant increase in REE among cancer patients with kidney and adrenal cancers reportedly causing the greatest elevations. A possible explanation for observed elevations among HCC and urologic cancer patients may be due to its usual metabolic demands when in a non-diseased state. It has been proposed by Holliday, as discussed by Weinsier et al [40] , that large internal organs, such as the liver and kidneys, could produce similar REE to that of skeletal muscle. Additionally, when in a diseased state, the liver serves a role in inflammation and increased energy production via gluconeogenesis which could potentially further elevate REE [11, 28] . This may mean that some organs become more metabolically demanding when they are cancerous and this may contribute to the increased metabolic rate. Due to the limited number of studies for both these cancer types, it would be difficult to derive any valid conclusions regarding changes in REE.
Studies investigating gastric and colorectal cancers consistently presented insignificant changes in REE when compared to healthy control groups. Cao et al [4] 4 found elevations in gastric cancer patients but observed unchanged REE in patients with colorectal cancer. Other authors [3, 7, 16, 18, 19, 21 , 29] saw insignificant changes. Two studies [3, 16] reported unchanged REE among gastric-colorectal cancer patients. However, this could be explained by the authors' use of the same gastric-colorectal cancer patients in both studies. This is important to consider as this factor could also affect the findings of this present study. Two authors [16, 28] 4 reported the presence of liver metastasis amongst certain patients with gastric and colorectal cancers with mixed conclusions in relation to REE. Fredrix et a [16] observed nil elevations in REE amongst patients with liver metastasis, whereas Lieffers et al [28] concluded that the presence of metastasis would contribute to elevated REE. Given that metastasis would produce a greater tumour burden, it is valid to believe REE would be further elevated in these patients. However, this review is unable to support this notion due to the small number of included studies which reported the effects of metastasis on REE and its conflicting findings.
Another factor which may affect energy expenditure is gender and whether the patients are weight stable or losing weight. Nixon et al [29] reported elevations in REE, although not statistically significant, only in weight-losing and weight-stable female colon cancer patients whereas male patients experienced slightly lower or unchanged REE when compared to control participants despite no correlations being made between REE and caloric intake. Although a secondary analysis demonstrated there was no difference between weight losing and weight stable patients only 5 studies reported these subgroups. We also investigated the differences in gender however only 2 studies reported results by gender and no differences were found. The dataset as a whole contained a larger proportion of males to females (Table 1) . Although it is anticipated much of the gender difference is related to body composition there maybe additional gender specific affects which could not be examined in this analysis.
Limitations and recommendations
There were a limited number of patients that have been studied in each of the cancer subtypes. Results from this study should, therefore, be interpreted with caution as more data was available for analysis of REE in lung, gastric and colon cancers. Available data for liver pancreatic and head and neck cancers were rather limited, and the derived alterations in REE would lack statistical power. Some studies in this review were published by the same authors who have utilised the same research methodology, and the statistical analyses had several data entries contributed by the same authors. Unique subgroups in these papers were analysed as independent samples [15] and the sample size was adjusted to accommodate the use of the same control group [14] , Despite this some authors may have used the same subject data in different studies making the total number of independent subjects uncertain..
The majority of studies were published before 2000 with only 6 studies published in the last 5 years, although we investigated this in a secondary analysis and did not see any differences, advances in cancer treatment may have an effect on metabolism. Table 1 also shows differences in the methodology used to assess energy expenditure (although indirect calorimetry using a ventilated hood was the primary method) and body composition methodology. Several studies used field methods to assess body composition reducing the quality of the studies although this did not have an effect on the results using meta regression. This analysis did not consider several other cancers known to raise REE.Haematological cancers and sarcomas have been reported to raise REE[41, 42] and these findings could serve an insightful addition to the current study. Due to the exclusion criteria used, these and other studies which published findings about other types of cancers not mentioned in this study were unable to be included.
Studies investigating cancer and metabolic rate often measure REE using body weight instead of FFM which resulted in the exclusion of many studies in this analysis. Although FFM is often regarded as a more accurate indicator of REE [9, 10] , many studies did not adjust REE for FFM. Furthermore, 40% of the included studies used the Harris-Benedict equation (HBE) to compare differences in energy expenditure instead of healthy control groups and, therefore, were not used in the analyses. It has been widely acknowledged the HBE tend to underestimate REE in healthy individuals. Daly et al [43] found the use of HBE to predict energy expenditure may not be a valid or reliable approach as it overestimated REE by 10.4% in healthy individuals, whereas Campbell et al [44] observed underestimations between 9-23% in critically ill and underweight male patients. Therefore, REE derived from the HBE may not be applicable to be used as a reference for comparison in cancer patients. Therefore, future investigations that measure REE adjusted for FFM and use healthy control groups would be advantageous in contributing to current knowledge regarding the cancer types discussed in this study and also other cancer types known to generate metabolic abnormalities, such as leukaemias.
Cancer cachexia was often discussed by authors as the background for conducting the respective studies. Yet, cachexia was not definitively identified in study patients and patients who experienced a large amount of weight loss (>10% of usual body weight) may have experienced varying degrees of cachexia. As cachexia greatly involves the inflammatory response and altered energy metabolism, REE would subsequently increase. If this was the case, the measured REE of patients who experienced large amounts of weight loss would skew the results reported by the authors and the results of this meta-analysis.
In conclusion, this meta-analysis supports current evidence of elevated REE in cancer patients when compared to healthy control participants with an observed 8-9% increase. Additionally, this study emphasised the heterogeneity observed among cancer types in REE. Due to the exclusion of many studies, not all cancer types were included in the meta-analysis as the results were not expressed as REE based on FFM. Further investigation of alterations in energy expenditure based on FFM can assist to clarify previous findings, in particular for cancer types not included in this review, and to provide renewed data. New data will build the current evidence base for the provision of additional nutrition support to compensate for elevated energy consumption in metastatic cancer patients [14] .
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